Table 2.
Inflammatory and immune-nutritional prognostic markers and its distribution among the study population.
| Inflammatory or Immune-Nutritional Marker | Score | Patients n 282 n (%) |
|---|---|---|
| Glasgow Prognostic Score (GPS) | ||
| CRP ≤ 10 mg/L and albumin ≥ 35 g/L | 0 | 192 (68.1) |
| CRP ≤ 10 mg/L and albumin < 35 g/L | 1 | 22 (7.8) 41 (14.5) |
| CRP > 10 mg/L and albumin ≥ 35 g/L | 1 | |
| CRP > 10 mg/L and albumin < 35 g/L | 2 | 27 (9.6) |
| Modified Glasgow Prognostic Score (mGPS) | ||
| CRP ≤ 10 mg/L and albumin ≥ 35 g/L | 0 | 192 (68.1) 22 (7.8) |
| CRP ≤ 10 mg/L and albumin < 35 g/L | 0 | |
| CRP > 10 mg/L and albumin ≥ 35 g/L | 1 | 41 (14.5) |
| CRP > 10 mg/L and albumin < 35 g/L | 2 | 27 (9.6) |
| Prognostic Index (PI) | ||
| CRP ≤ 10 mg/L and WBC ≤ 11 × 109/L | 0 | 200 (70.9) |
| CRP ≤ 10 mg/L and WBC > 11 × 109/L | 1 | 50 (17.7) |
| CRP > 10 mg/L and WBC ≤ 11 × 109/L | 1 | 8 (2.8) |
| CRP > 10 mg/L and WBC > 11 × 109/L | 2 | 24 (8.5) |
| Neutrophil to lymphocyte ratio (NLR), median (IQR) | 3.09 (2.04–4.05) | |
| NLR < 3.13 * | 0 | 146 (51.8) |
| NLR ≥ 3.13 * | 1 | 136 (48.2) |
| Platelet to lymphocyte ratio (PLR), median (IQR) | 160.4 (117.3–230.3) | |
| PLR < 178.2 * | 0 | 174 (61.7) |
| PLR ≥ 178.2 * | 1 | 108 (38.3) |
| Lymphocyte to monocyte ratio (LMR), median (IQR) | 3.34 (2.39–4.62) | |
| LMR < 3.47 * | 1 | 156 (55.3) |
| LMR ≥ 3.47 * | 0 | 126 (44.7) |
| Prognostic Nutritional Index (PNI), median (IQR) | 49.4 (44.3–53.6) | |
| Albumin (g/L) + 5 × total lymphocyte count < 48.6 * | 1 | 128 (45.4) |
| Albumin (g/l) + 5 × total lymphocyte count ≥ 48.6 * | 0 | 154 (54.6) |
GPS, Glasgow Prognostic Score; mGPS, modified Glasgow Prognostic Score; PI, Prognostic Index; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PNI, prognostic nutritional index; CRP, C-reactive protein; WBC, white blood cells; IQR, Interquartile range; * The optimal cut-off of NLR, PLR, LMR e PNI was determined by ROC curves analysis.